- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
GENFIT Publishes 2026 ESG Report, Achieves B Corp Certification
Biopharmaceutical company highlights progress on societal, environmental, and governance initiatives in 2025
Apr. 20, 2026 at 4:20pm
Got story updates? Submit your updates here. ›
GENFIT's commitment to sustainability and ethical practices is reflected in its innovative pharmaceutical research and development.Cambridge TodayGENFIT, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, has published its 2026 extra-financial performance report (fiscal year 2025) and announced its achievement of B Corp certification. The report details the company's progress on its ESG roadmap, including initiatives focused on the medical ecosystem, employee engagement, governance, and environmental impact.
Why it matters
GENFIT's commitment to ESG principles and its B Corp certification demonstrate the company's holistic approach to business, balancing financial performance with positive social and environmental impact. This aligns with growing investor and stakeholder expectations for companies to be responsible corporate citizens.
The details
In 2025, GENFIT implemented around 30 ESG initiatives involving all employees. Societal actions focused on mobilizing the medical, scientific, and regulatory ecosystem to position acute-on-chronic liver failure (ACLF) as a strategic priority. Socially, the company maintained high employee engagement and gender equality. Governance efforts strengthened cyber risk management and the responsible use of artificial intelligence. Environmental initiatives were also implemented to better control the company's footprint.
- GENFIT published its 2026 extra-financial performance report in April 2026, covering fiscal year 2025.
- GENFIT achieved B Corp certification in 2025.
The players
GENFIT
A biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases.
Pascal Prigent
Chief Executive Officer of GENFIT.
Larry Holden
President of the Global Liver Institute, an international patient organization for liver diseases.
Aurélie Leclercq
Executive Director of the Endowment Fund of Lille University Hospital.
What they’re saying
“Collective engagement, dialogue with external stakeholders, rigor and ethical practices, as well as effective risk management, are inseparable from GENFIT's ability to execute its strategy while maintaining trust with its stakeholders. These fundamentals are what make our operational and clinical progress possible, with a clear objective: delivering tangible benefits to patients.”
— Pascal Prigent, Chief Executive Officer of GENFIT
“Through GENFIT's ACLF Patient Advocacy Council, we have witnessed genuine engagement with patients and caregivers, along with a real effort to develop awareness materials that are meaningful and useful to them. Our perspectives are heard and acted upon, in an area marked by a particularly acute unmet medical need, with no approved therapeutic options, very limited research and still insufficient knowledge. B Corp certification reflects the ongoing dialogue we have with GENFIT and goes far beyond a simple marketing claim.”
— Larry Holden, President of the Global Liver Institute
“The support of committed partners such as GENFIT illustrates the importance of solidarity at the regional level in enabling innovative healthcare projects with high societal impact. GENFIT's contribution to the development of the unit dedicated to Adolescents and Young Adults at Lille University Hospital aims to secure care pathways and facilitate the transition from pediatric to adult medicine. Last year's commitment has already translated into the creation of a single dedicated reception facility for all victims of violence, offering them a comprehensive and secure care pathway.”
— Aurélie Leclercq, Executive Director of the Endowment Fund of Lille University Hospital
What’s next
GENFIT's 2026 roadmap will build on the momentum achieved in 2025, continuing to advance its ESG initiatives and drive progress in its therapeutic and diagnostic pipelines.
The takeaway
GENFIT's commitment to ESG principles and its achievement of B Corp certification demonstrate the company's holistic approach to business, balancing financial performance with positive social and environmental impact. This aligns with growing stakeholder expectations for responsible corporate citizenship.
